Antibody Discovery: From Target to Molecule
Considerations and approaches for the Biopharma Industry
You’re about to embark on a journey of discovery. And like all journeys that are worthwhile, it’s far from linear. The process of antibody discovery and development into a clinical candidate is one full of twists, turns, roundabouts, and offshoots, yet one that an increasing number of researchers and companies, both small and large, have successfully navigated.
At least 570 mAbs have already been progressed to the clinic by commercial companies. Each one has been on a long journey of development, with most companies taking approximately 12 years to move from the first patent filing to FDA approval. The multi-year journey may feel overwhelming, but it can be broken up into short-term goals and milestones.
As recently as the past decade, much has changed in antibody discovery, optimisation, and development. New techniques have made this entire process more rapid, cost-effective, and targeted. This guide is here to help you throughout this journey.
What follows is your handbook for the modern antibody development process.
In this eBook you will learn how to: